Prenatal Dx Startup KellBenx, Inc. Eyes $10 Million in Funding Round

Published: Jul 24, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A New York startup is aiming to provide an alternative to the traditional prenatal blood tests by developing a DNA test that analyzes fetal cells that are intact within a maternal blood sample. The company - KellBenx - is seeking $10 million, according to a regulatory filing. Previously, it appears to have raised $2.5 million in the second quarter of 2011. Aside from developing a non-invasive, DNA-based diagnostic test to detect genetic abnormalities in fetuses, KellBenx is also aiming to develop a breakthrough test to determine a pregnant woman's chances of delivery prematurely.

Help employers find you! Check out all the jobs and post your resume.

Back to news